Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Dörr
J
J
NeuroCure Clinical Research Center, Charité-Universitaetsmedizin Berlin, 10117 Berlin, Germany.
Bitsch
A
A
Schmailzl
K J G
KJ
Chan
A
A
von Ahsen
N
N
Hummel
M
M
Varon
R
R
Lill
C M
CM
Vogel
H-P
HP
Zipp
F
F
Paul
Friedemann
F
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000503:physiopathology; D024061:Collagen Type III / Q000032:analysis / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006333:Heart Failure / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D008942:Mitoxantrone / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009363:Neoplasm Proteins / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics; D011654:Pulmonary Edema / Q000139:chemically induced / Q000503:physiopathology; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced / Q000503:physiopathology
C513055:ABCB1 protein, human; C116614:ABCG2 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D024061:Collagen Type III; D009363:Neoplasm Proteins; D008942:Mitoxantrone